Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells

Yasuhiro Mitsuuchi,Christopher A. Benetatos,Yijun Deng,Thomas Haimowitz,Sc Beck,Arnone,Gurpreet S. Kapoor,Martin E. Seipel,Srinivas K. Chunduru,Mark A. McKinlay,Cg Begley,Stephen M. Condon

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells

2017

Yasuhiro Mitsuuchi
Christopher A. Benetatos
Yijun Deng
Thomas Haimowitz
Sc Beck
Arnone
Gurpreet S. Kapoor
Martin E. Seipel
Srinivas K. Chunduru
Mark A. McKinlay
Cg Begley
Stephen M. Condon

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF- κ B signaling by degrading TRAF2-associated cIAP1 in cancer cells

Keywords:

Cancer cell
Tumor necrosis factor alpha
Cancer research
TRAF2
Virology
NF-κB
Bivalent (genetics)
Biology
Pharmacology
Programmed cell death
Immunology
Cancer
Inhibitor of apoptosis
Ubiquitin ligase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations